By Spondylitis Association of America
Since its founding more than 35 years ago, the Spondylitis Association of America (SAA) has been at the forefront of funding research for a cure for spondyloarthritis (SpA). Embracing its mission to be the leading national nonprofit in the fight for a cure and to advocate on behalf of all people impacted by the chronic illness, SAA continues to identify and support ground-breaking research projects through its SAA/Bruckel Early Career Investigator Award in AxSpA (ECI) and additional grants for exploratory research.
Better ways to measure spinal fusion are needed to be able to evaluate the effectiveness of medicines in slowing or stopping spinal fusion. This study hopes to answer the question of whether CT scanning of the spine can provide a reliable, valid, and sensitive measure of spinal fusion in ankylosing spondylitis.
A Netherlands’ clinical trial assessed the effectiveness of the TNF inhibitor golimumab in reducing the recurrence of Acute Anterior Uveitis (AAU), eye inflammation, in ankylosing spondylitis.
In November, and in the spirit of Thanksgiving, the online Spondylitis Community recognized and thanked individuals who make a positive difference in their lives. Did you take part?
A Phase 3 clinical trial is now recruiting patients over the age of 18 with active ankylosing spondylitis (AS) to participate.
The purpose of the trial, titled, “Efficacy and Safety of Tofacitinib in Subjects with Active Ankylosing Spondylitis (AS)” is to determine if Tofacitinib is safe and effective in subjects with active ankylosing spondylitis
Visit our careers page for available positions
16360 Roscoe Blvd. Ste. 100Van Nuys, CA 91406
(800) 777-8189 U.S. only
or (818) 892-1616*Please note: This is not a Crisis Hotline. If you are in a life-threatening crisis, please dial 911 for immediate help in the US. Please follow this link for crisis intervention resources.